Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
The Journal of Chemical Physics|June 17, 2008
Characterization of Lewis acid sites on the (100) surface of beta-AlF3: Ab initio calculations of NH3 adsorptionC L Bailey, A Wander, S Mukhopadhyay, et al.
Cancer Cell|February 10, 2026
Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancerJuan Luis Gomez Marti, Elena Michaels, Azadeh Nasrazadani, et al.
Breast Cancer Research and Treatment|July 7, 2025
A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesionShivahamy Maheswaran, Arielle J Medford, Tomasz P Stryjewski, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Physical Chemistry Chemical Physics : PCCP|April 15, 2010
Reactivity of the beta-AlF(3)(100) surface: defects, fluorine mobility and catalysis of the CCl(2)F(2) dismutation reactionC L Bailey, S Mukhopadhyay, A Wander, et al.
Expert Review of Anticancer Therapy|April 20, 2024
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-childJennifer C Keenan, Arielle J Medford, Charles S Dai, et al.
Brain Research Bulletin|March 11, 1992
Anterograde transport of HSV-1 and HSV-2 in the visual systemR B Norgren, J H McLean, H C Bubel, et al.
The Oncologist|August 2, 2022
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to AbemaciclibSeth A Wander, Neil O'Brien, Lacey M Litchfield, et al.
NPJ Breast Cancer|June 12, 2026
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancerS A Wander, C M Weipert, L Cabel, et al.
Physical Review Letters|May 1, 2001
Stability of polar oxide surfacesA Wander, F Schedin, P Steadman, et al.
Pageof 9